HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorRenJi Hospital
About this trial
Patients with unresectable HCC will be enrolled in the cohort and will receive the combination therapy of HAIC and atezolizumab plus bevacizumab. The objective response rate is the primary endpoint, and the secondary endpoint includes disease control rate, conversion rate, pathologic complete response, major pathologic response, progression-free survival, recurrence-free survival, overall survival, quality of life, and safety.
Eligibility criteria
Qualifiers
Patients between 18 and 75 years old, with no gender restrictions.
Confirmed unresectable hepatocellular carcinoma (BCLC stage B/C) by histology, cytology, or clinical diagnosis.
At least one measurable lesion based on RECIST version 1.1.
Child-Pugh class A or B7.
Disqualifiers
Known intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma, sarcomatoid HCC, or fibrolamellar carcinoma.
Concurrent autoimmune diseases, organ/hematopoietic stem cell transplantation history, or other malignancies.
Impaired consciousness, inability to cooperate with treatment, or active psychiatric disorders.
Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), bevacizumab, molecular targeted therapy, atezolizumab, or other PD-1/PD-L1 inhibitors received before enrollment.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
28 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov